Abstract | BACKGROUND: METHODS: Patients with CDH who were treated by PEG-IFN-α2a or -2b for 24 months were included in the study. Demographic, biochemical and virological parameters were recorded at baseline and during follow-up. All included patients completed a treatment period of 24 months and at least a 6 month (range 6-60) follow-up period. Biochemical and virological response rates at end of treatment and end of follow-up were calculated, and predictors of sustained virological response (SVR) were analysed. RESULTS: In total, 32 patients (22 males; mean age ± SD 42.7 ± 12 years) with CDH who were treated with PEG-IFN-α2a (180 µg) or -2b (1.5 µg/kg) once a week subcutaneously for 24 months were included in the study. All patients had compensated liver disease (25 [78%] were non-cirrhotic), increased transaminase levels and HDV RNA positivity at baseline. Genotypic analyses of HDV showed genotype I in all. Mean duration of follow-up was 19.5 months. At the end of treatment, virological response was achieved in 16 (50%) patients. SVR at the end of follow-up was achieved in 15 (47%) patients. A negative HDV RNA at 6 months of treatment was the only predictor of SVR (OR = 20; 95% CI 2, 195; P = 0.01). CONCLUSIONS: PEG-IFN-α treatment achieved SVR in approximately half of the patients with CDH, and relapse rate was very low during the follow-up. Negativity of HDV RNA at 6 months may predict SVR in CDH.
|
Authors | Cetin Karaca, Ozlem M Soyer, Bulent Baran, Asli C Ormeci, Suut Gokturk, Esra Aydin, Sami Evirgen, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 18
Issue 4
Pg. 561-6
( 2013)
ISSN: 2040-2058 [Electronic] England |
PMID | 22976528
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- Interferon alpha-2
- Interferon-alpha
- RNA, Viral
- Recombinant Proteins
- Polyethylene Glycols
- peginterferon alfa-2b
- peginterferon alfa-2a
|
Topics |
- Adolescent
- Adult
- Antiviral Agents
(therapeutic use)
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Hepatitis D, Chronic
(blood, diagnosis, drug therapy, virology)
- Hepatitis Delta Virus
(drug effects, physiology)
- Humans
- Interferon alpha-2
- Interferon-alpha
(therapeutic use)
- Male
- Middle Aged
- Molecular Typing
- Polyethylene Glycols
(therapeutic use)
- Prognosis
- RNA, Viral
(antagonists & inhibitors, blood)
- Recombinant Proteins
(therapeutic use)
- Treatment Outcome
- Viral Load
(drug effects)
|